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Abstract
The anterior pituitary is under a constant cell turnover modulated by gonadal steroids. In the rat, an increase in the rate of
apoptosis occurs at proestrus whereas a peak of proliferation takes place at estrus. At proestrus, concomitant with the
maximum rate of apoptosis, a peak in circulating levels of prolactin is observed. Prolactin can be cleaved to different N-
terminal fragments, vasoinhibins, which are proapoptotic and antiproliferative factors for endothelial cells. It was reported
that a 16 kDa vasoinhibin is produced in the rat anterior pituitary by cathepsin D. In the present study we investigated the
anterior pituitary production of N-terminal prolactin-derived fragments along the estrous cycle and the involvement of
estrogens in this process. In addition, we studied the effects of a recombinant vasoinhibin, 16 kDa prolactin, on anterior
pituitary apoptosis and proliferation. We observed by Western Blot that N-terminal prolactin-derived fragments production
in the anterior pituitary was higher at proestrus with respect to diestrus and that the content and release of these prolactin
forms from anterior pituitary cells in culture were increased by estradiol. A recombinant preparation of 16 kDa prolactin
induced apoptosis (determined by TUNEL assay and flow cytometry) of cultured anterior pituitary cells and lactotropes from
ovariectomized rats only in the presence of estradiol, as previously reported for other proapoptotic factors in the anterior
pituitary. In addition, 16 kDa prolactin decreased forskolin-induced proliferation (evaluated by BrdU incorporation) of rat
total anterior pituitary cells and lactotropes in culture and decreased the proportion of cells in S-phase of the cell cycle
(determined by flow cytometry). In conclusion, our study indicates that the anterior pituitary production of 16 kDa prolactin
is variable along the estrous cycle and increased by estrogens. The antiproliferative and estradiol-dependent proapoptotic
actions of this vasoinhibin may be involved in the control of anterior pituitary cell renewal.
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Introduction
In sexually mature female mammals, hypothalamic, pituitary
and ovarian hormones have particular secreting profiles that
define the endocrine environment of each stage of the estrous
cycle. In the rat anterior pituitary, cell renewal is also a cyclic
phenomenon. In each estrous cycle a peak of proliferation occurs
at estrus whereas the highest rate of apoptosis is observed during
proestrus [1,2]. The cell turnover that takes place in the rat
anterior pituitary is a highly regulated process in which several
factors were demonstrated to participate. Estradiol, by the induc-
tion of apoptosis per se or by sensitizing cells to different pro-
apoptotic factors such as TNF-a, FasL and dopamine, plays a key
role in anterior pituitary gland remodeling [3–7].
Prolactin plasma levels are relatively constant along the estrous
cycle, except during proestrus, when an abrupt increase in its secre-
tion takes place, mainly due to the concomitant high circulating
levels of estrogens [8]. Apart from the 23 kDa native protein,
prolactin is present as several molecular forms that include
phosphorylated, glycosylated, and lower molecular weight proteins
[9]. Enzymatic cleavage of 23 kDa prolactin produces 14 to 18 kDa
amino-terminal fragments with antiangiogenic effects, known as
vasoinhibins [10]. 16 KDa prolactin has been strongly related
to antiproliferative and proapoptotic actions in endothelial cells
inducing cell cycle arrest [11], caspase activation [12,13], modu-
lation of Bcl-2 protein family [13] and NFkB activation [13].
It has been shown that a 16 kDa amino terminal fragment is
produced in the anterior pituitary gland by cathepsin D [14]. Like
prolactin expression, 16 kDa prolactin production in this gland
could also be a hormone-regulated process. In fact, Souto et al sug-
gested that its rate of production could be gender-dependent [14].
In this work, we investigated the production of anterior pituitary
N-terminal prolactin fragments along the estrous cycle and the
effect of estradiol on their content and release. Because of vasoinhibins
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21806reported actions on endothelial cells [10], we also studied whether
16 kDa prolactin is involved in the control of anterior pituitary cell
renewal.
Materials and Methods
Drugs
All drugs, media and supplements were obtained from Invi-
trogen (Carlsbad, CA, USA), except Dulbecco’s modified Eagle’s
medium (DMEM), EDTA, bovine serum albumin (BSA), 17
b-estradiol, bromodeoxyuridine (BrdU), protease inhibition kit,
normal donkey and sheep sera, anti b-actin antibody, deoxyribo-
nuclease type I, forskolin (Sigma, St. Louis, MO, USA), fetal
bovine serum (Natocor, Argentina), all terminal deoxynucleotidyl
transferase-mediated deoxyuridine triphosphate nick end-labeling
(TUNEL) reagents (Roche Molecular Biochemicals, Mannheim,
Germany), guinea pig rat prolactin antiserum, anti-recombinant
rat prolactin antiserum (rrPRL) (Dr. A. Parlow, National Hor-
mone and Pituitary Program, Torrance, CA, USA), anti-BrdU
(BD Bioscience) anti-guinea pig rhodamine-conjugated secondary
antibody, anti-mouse fluorescein isothiocyanate (FITC) conjugat-
ed secondary antibody, streptavidin horseradish peroxidase (HRP)
conjugated anti-rabbit antibody (Chemicon International, Teme-
cula, CA, USA) and the materials indicated below.
Animals
Adult female Wistar rats were kept in controlled conditions
of light (12-hour light-dark cycles) and temperature (20–25uC).
Rats were fed standard lab chow and water ad libitum and kept
in accordance with the NIH Guide for the Care and Use of
Laboratory Animals. All the procedures were in compliance with
the Ethical Committee of the School of Medicine, University of
Buenos Aires (Res. (CD) Nu 2831/10). Rats were ovariectomized
(OVX) under ketamine (100 mg/kg, i.p.) and xylazine (10 mg/kg,
i.p.) anesthesia 2 weeks before the experiments. Anterior pituitary
glands were removed within minutes after decapitation and pro-
cessed for primary culture. In addition, cycling female rats were
monitored by daily vaginal smears. Rats with three or more
normal consecutive 4–5 day estrous cycles were killed between
12:30 pm and 1 pm of diestrus I or proestrus. Anterior pituitaries
from cycling rats were processed for protein extraction.
Anterior pituitary primary culture
A pool of anterior pituitaries from 3–4 OVX rats was used for
each culture. The glands were washed with Dulbecco’s Modified
Eagle Medium supplemented with 10 ml/ml MEM amino acids,
2 mM glutamine, 5.6 mg/ml amphotericin B, 25 mg/ml gentami-
cin (DMEM) and 3 mg/ml BSA. Then, anterior pituitaries were
cut into small fragments. Sliced fragments were dispersed
enzymatically by successive incubations in DMEM-BSA contain-
ing 0.75% trypsin, 10% fetal calf serum previously treated with
0.025% dextran-0.25% charcoal to remove steroids (FCS), and
45 U/ml deoxyribonuclease type I (DNAse). Finally, the cells were
dispersed by extrusion through a Pasteur pipette in Krebs buffer
without Ca
2+ and Mg
2+. Dispersed cells were washed and
resuspended in DMEM with 10% FCS. Cell viability as assessed
by trypan blue exclusion was over 90%. Dispersed cells were
seeded onto 24-well tissue culture plates for BrdU incorporation
detection, TUNEL assay or culture media analysis (1.5–2610
5
cells/ml/well), for flow cytometry (FACS) (3610
5 cells/ml/well)
and for protein extraction (1610
6 cells/ml/well). Cells were
cultured for 24 h in DMEM with 10% FCS (DMEM-FCS) and
then incubated for 24 h in DMEM-FCS containing ethanol (1 ml/
l, VEH) or 17b-estradiol (10
29 M, E2) for the detection of
N-terminal prolactin fragments in anterior pituitary cells and
culture media. For apoptosis and cell cycle evaluation experi-
ments, cells were incubated for 19 h in DMEM without FCS in
the presence of VEH or E2. Then, cells were incubated with the
same fresh media for 1 h and then incubated for further 4 h in the
same media with or without 16 kDa prolactin (16 kDa PRL,
10 nM) [15]. Since BrdU incorporation (3 h) was not detected in
cells cultured in DMEM-FCS (data not shown), for proliferation
studies cells were incubated in the presence of forskolin (1 mM,
FSK), which induces anterior pituitary cell proliferation in vitro
[16]. In some experiments cells were incubated for 19 h with FSK
and VEH. Then, cells were incubated with the same fresh media
for 1 h and then for further 4 h in the same media with or without
16 kDa PRL (10 nM). In other experiments, cells were incubated
for 19 h with E2. Then, cells were incubated with FSK and E2 for
1 h and then, for further 4 h in the same media with or without
16 kDa PRL (10 nM). Three hours before fixation, BrdU
(200 mM) was added to the culture media. Recombinant 16 kDa
PRL (16 kDa PRL) was obtained as previously described [17].
Western blot
Total proteins were extracted from anterior pituitary glands or
from cultured anterior pituitary cells with lysis buffer containing
250 mM NaCl, 5 mM MgCl2, 50 mM NaF, 1 mM dithiothreitol,
1% Igepal, 0.02% sodium azide, 0.1% sodium dodecyl sulphate
(SDS), in 50 mM Tris-HCl pH 7.4 and a protease inhibitor kit
(1:100). Following homogenization and centrifugation at 16000 rcf
for 30 min, the supernatant was used for the immunoblot assay.
The protein concentration of each sample was determined by
the Bradford protein assay (BioRad Laboratories, CA, USA).
Thirty mg of total proteins or 15 ml of culture media from an-
terior pituitary cells in culture were size-fractionated in 15% SDS-
polyacrylamide gel and then electrotransferred to polyvinyl
difluoride (PVDF) membranes. Blots were incubated for 90 min
in 5% nonfat dry milk-TBS-0.1% Tween 20 at room temperature
and incubated overnight with the appropriate primary antibody in
the same buffer at 4uC. The primary antibodies used were: anti-rat
recombinant PRL (anti-rrPRL 1:10000 to 1:25000) and anti b-
actin (1:5000). This was followed by 1 h incubation with the
corresponding secondary antibody conjugated with HRP. Proteins
incubated with buffer without primary antibody were used as
negative controls. Immunoreactivity was detected by enhanced
chemoluminescence (Productos Bio-Lo ´gicos, Argentina). Chemo-
luminiscence was detected by chemoluminiscence imaging system
(G Box Chemi HR16, Syngene) and bands were quantified using
Gene Tools software (Syngene). Intensity data were normalized
with respect to the corresponding b-actin blot. Data were ex-
pressed as relative increment to respective controls.
TUNEL, BrdU incorporation and Immunocytochemistry
After the incubation period, cultured cells were fixed with 4%
paraformaldehyde for 10 min and permeabilized by microwave
irradiation. For TUNEL assay, DNA strand breaks were labeled
with digoxigenin-deoxyuridine triphosphate using terminal deox-
ynucleotidyl transferase (0.18 U/ml) according to the manufactur-
er’s protocol. After incubation with 10% normal donkey serum
and 10% normal sheep serum in PBS for 90 min, cells were
incubated for 1 h with guinea pig rat prolactin antiserum (1:1500).
Then, slides were incubated with antidigoxygenin-fluorescein
antibody (1:10) to detect incorporation of nucleotides into the
39-OH end of damaged DNA and rhodamine-conjugated anti-
guinea pig secondary antibody (1:200) in the same buffer. For
BrdU incorporation assay, the slides were incubated 30 min with
DNAse (45 U/ml) at 37uC to break DNA strands and to allow
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cells were blocked 90 min with 10% horse serum in PBS- 0.2%
Triton and then incubated with mouse anti-BrdU antibody (1:200)
overnight. The next day, slides were incubated with a FITC-
conjugated anti-mouse secondary antibody (1:200). After incuba-
tion with 10% normal donkey serum in PBS-0.2% Triton for
90 min, cells were incubated for 1 h with guinea pig rat prolactin
antiserum (1:1500) followed by 1 h incubation with rhodamine-
conjugated anti-guinea pig secondary antibody (1:200). Control
slides were incubated with normal serum instead of primary
antibodies. Slides were mounted with Vectashield (Vector Labo-
ratories, Inc., Burlingame, CA, USA) containing 4, 6 diamidino-
2-phenylindoledihydrochloride (DAPI) for DNA staining and
visualized in a fluorescent light microscope (Axiophot; Carl Zeiss,
Jena, Germany). The percentage of lactotropes determined by
immunocytochemistry represented 25–40% of the population of
anterior pituitary cells. The percentage of apoptotic (TUNEL-
positive) or proliferating (BrdU-positive) anterior pituitary cells
was calculated as (TUNEL-positive or BrdU-positive cells/total
anterior pituitary cells)6100; and the percentage of apoptotic
or proliferating lactotropes was calculated as (TUNEL-positive
or BrdU-positive prolactin-immunoreactive cells/total prolactin-
immunoreactive cells)6100.
Flow cytometry
Cultured anterior pituitary cells from OVX rats were harvested
with 0.05% trypsin-EDTA. Cells of each well were washed with
PBS, resuspended in 300 ml of PBS-0.1% BSA and added for
fixation into 5 ml of 70% ice-cold methanol by gentle vortexing.
Cells were fixed for 30 min at 220uC. Then, 5 ml of PBS-0.1%
BSA were added to each tube. After centrifugation, DNA was
stained with propidium iodide (PI, 50 mg/ml) in PBS containing
ribonuclease (10 mg/ml) at 37uC for 20 min. Fluorescence inten-
sity of $6000 gated cells/tube was analyzed by flow cytometry
using a FACScan (Becton Dickinson). Cells with a PI staining
intensity lower than the G0/G1 peak were considered hypodip-
loid. Analysis of hypodiploid or S-phase DNA content was per-
formed using WinMDI 98 and Cylcherd 1.2 software.
Statistical Analysis
The number of TUNEL-positive cells and the number of BrdU
positive-cells were determined in slides from independent
experiments. Results were expressed as the percentage 695%
confidence interval (CI) of TUNEL-positive cells or BrdU-positive
cells of the total number of cells counted in each specific condition.
Differences between proportions were analyzed by x
2. The
percentage of hypodiploid cells or cells in S-phase of the cell
cycle were expressed as mean 6 SE and analyzed by unpaired
Student’s t test. Western blot data were expressed as mean 6 SE
and analyzed by unpaired Student’s t test. Differences were
considered significant if p,0.05. Statistical analysis was performed
using GraphPad Prism 4 software.
Results
N-terminal PRL fragments content in the anterior
pituitary along the estrous cycle
To evaluate the ability of the anti-rrPRL to bind to 23 kDa PRL
and N-terminal PRL fragments present in the anterior pituitary
[14], we tested its reactivity against recombinant 16 kDa PRL,
recombinant 23 kDa PRL and protein extracts obtained from
anterior pituitaries of female rats by Western blot. As shown in
Figure 1A, the antibody recognized 23 kDa PRL and 16 kDa
N-terminal PRL standards. Additionally, 23 kDa and <16 kDa
bands were also visible when protein extracts from the anterior
pituitary were run under reducing and non-reducing conditions.
As previously described by Cruz-Souto et al., a higher intensity in
the <16 kDa band was observed under reducing conditions [14]
(Fig. 1A). The 23 kDa and <16 kDa variants were also recognized
by an anti-N-terminal PRL fragment antibody as previously
described [14] (data not shown).
Figure 1. N-terminal PRL fragments content in the anterior
pituitary varies along the estrous cycle. A: Recombinant 23 kDa
PRL (r23-PRL), recombinant 16 kDa prolactin (r16-PRL) or pituitary
protein extracts treated with b-mercaptoethanol (P+b,r e d u c i n g
conditions) or without b-mercaptoethanol (P, non-reducing conditions)
were incubated with anti-recombinant rat PRL antibody (anti rrPRL,
1:25000). The antibody recognizes both PRL forms. B: Anterior
pituitaries from rats euthanized at diestrus I or proestrus were
processed for western blot. Upper panel: Each column represents the
mean 6 SE of the relative increment of N-terminal PRL fragments
content with respect to diestrus I. Data of each column were
normalized to b-actin expression (n=4–7 animals per group).
*p,0.01 vs. diestrus I, Student’s t test. Lower panel: Representative
blot of pituitary proteins from rats euthanized at diestrus I or proestrus.
doi:10.1371/journal.pone.0021806.g001
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of anterior pituitary cell apoptosis is the highest, we evaluated if
the content of N-terminal PRL fragments in the anterior pituitary
changes during the estrous cycle. Protein extracts from anterior
pituitaries of female rats euthanized at proestrus or diestrus I were
analyzed by western blot using anti-rrPRL. The content of 16 kDa
PRL was higher in anterior pituitaries from rats euthanized at
proestrus than at diestrus I (Fig. 1B and 1C).
Production and release of N-terminal PRL fragments by
anterior pituitary cells
16 kDa PRL was previously shown to be produced by cultured
anterior pituitary cells from OVX-E2 treated rats [14]. To
evaluate if estrogens are involved in the increase of the content of
16 kDa PRL in the anterior pituitary observed during proestrus,
we incubated anterior pituitary cells from OVX rats in the pre-
sence or absence of E2. In vitro secretion and cellular content of
N-terminal PRL fragments were evaluated by western blot. The
presence of E2 induced an increase in both release (Fig. 2A) and
content (Fig. 2B) of 16 kDa PRL from anterior pituitary cells in
culture.
16 kDa PRL and apoptosis of anterior pituitary cells
To test the effect of 16 kDa PRL on anterior pituitary cell
apoptosis, primary cultures of anterior pituitary cells from OVX
rats were incubated with 16 kDa PRL (10 nM) [18] for 4 h and
evaluated by TUNEL. As E2 sensitizes anterior pituitary cells to
different proapoptotic stimuli [3–6,18], the apoptotic effect was
determined in the presence or absence of E2. As previously
described [6,19], E2 itself induced apoptosis of total anterior
pituitary cells. 16 kDa PRL increased the percentage of TUNEL-
positive cells and TUNEL-positive lactotropes only in the presence
of E2 (Fig. 3A and 3B). To confirm this effect, we evaluated the
percentage of hypodiploid cells by flow cytometry. In the presence
of E2, 16 kDa PRL increased the percentage of cells in Sub-G0/
G1 (Fig. 3C).
16 kDa PRL and anterior pituitary cell proliferation
To evaluate the effect of 16 kDa PRL on proliferation of total
anterior pituitary cells and lactotropes, primary cultures from
OVX rats were incubated in the presence of FSK with or without
E2. The effect of 16 kDa PRL (10 nM, 4 h) was evaluated by
BrdU incorporation. 16 kDa PRL decreased FSK-induced pro-
liferation in total anterior pituitary cells and lactotropes both in the
absence (Fig. 4A and B) and presence (Fig. 4D and E) of E2.
Additionally, we evaluated the effect of 16 kDa PRL on cell
cycle progression of anterior pituitary cells by flow cytometry.
Anterior pituitary cells from OVX rats were cultured with VEH or
E2 and then incubated for 4 h in the absence or presence of
16 kDa PRL (10 nM). Confirming its antiproliferative action
observed in BrdU incorporation studies, 16 kDa PRL decreased
the percentage of cells in S-phase in the absence (Fig. 4C) or
presence (Fig. 4F) of E2.
Discussion
It has been reported that 16 kDa PRL and other N-terminal
PRL-derived fragments have proapoptotic and antiproliferative
actions in endothelial cells. Because of its antiangiogenic pro-
perties, thisgroup ofmolecules is known as vasoinhibins[10].These
peptides are produced by proteolytic cleavage from 23 kDa
prolactin. Bone morphogenetic protein, matrix metalloproteinases
and cathepsin D have been involved in this process [20,10].
Cathepsin D is an aspartic protease with an optimum pH of 4.5–5.0
for its activity [21], therefore it may be active in lysosomal granules
wherethispHconditionoccurs.CathepsinDcanalsobe secretedto
the extracellular compartment [22] where its activity is controver-
sial due to the neutral pH of this environment. In bovine corpora
lutea, 23 kDa PRL conversion to 14 and 16 kDa fragments by
secreted cathepsin D was reported to be optimal at pH 3 and
inhibited at pH 7 [23]. However, it has been shown that mammary
gland epithelial cells secrete cathepsin D able to produce PRL-
derived 16 kDa products at pH 7 in the extracellular milieu
[21,24]. On the other hand, acidic pH in the extracellular
Figure 2. Estradiol increases the secretion and content of N-terminal PRL fragments from anterior pituitary cells in culture. Anterior
pituitary cells from OVX rats were incubated in the presence of VEH or E2 for 24 h. A: Culture media and B: cells were obtained and processed for
western blot analysis. Each column represents the mean 6 SE of the relative increment of N-terminal PRL fragments with respect to VEH. In B, data of
each column were normalized to b-actin expression (A, n=6 wells/group; B, n=6 wells/group), representative of three independent experiments.
*p,0.05, **p,0.01 vs. VEH without E2, Student’s t test. Lower panels: Representative blots of media (A) or cells (B) cultured with VEH or E2.
doi:10.1371/journal.pone.0021806.g002
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oxygen tension that can be found in tumors [25,26] Also, it was
shown that in normal conditions, a pericellular acidic pH can be
reached by the activity of the Na+/H+ exchanger and H+/ATPase
[24]. In anterior pituitary cells, cathepsin D is present in prolactin
secretory granules, and was proposed to be the main protease
involved in 16 kDa PRL production, as mice deficient for cathepsin
D do not generate vasoinhibins in the anterior pituitary gland [14].
Our present data show the presence of N-terminal PRL fragments
in cultured anterior pituitary cells and in the conditioned media as
Figure 3. 16 kDa PRL induces apoptosis of anterior pituitary cells. A and B: Anterior pituitary cells from OVX rats were incubated with VEH or
E2 for 24 h and with or without 16 kDa PRL (10 nM) for the last 4 h. A: Each column represents the percentage 6 CI (95%) of TUNEL-positive cells
(n$1500 cells/group, left) or TUNEL-positive lactotropes (n$300 cells/group, right), representative of four independent experiments. Data were
analyzed by x
2. **p,0.01 vs. respective control without 16 kDa PRL. ‘‘p,0.01, ‘p,0.05 vs. respective control without E2. B: Representative images
of anterior pituitary cells showing immunoreactivity for prolactin (red) counterstained with DAPI (blue, upper panels) and DNA fragmentation
determined by TUNEL method (green, lower panels). Arrowheads indicate apoptotic lactotropes. Scale bar: 50 mm. C: Anterior pituitary cells from OVX
rats were incubated with E2 for 24 h, and with or without 16 kDa PRL (10 nM) for the last 4 h. The percentage of hypodiploid cells was determined by
flow cytometry using PI. Left: Each column represents the mean 6 SE of the percentage of sub-G1 cells (n=3 wells/group), representative of three
independent experiments. Data were analyzed by Student’s t test. **p,0.01 vs. respective control without 16 kDa PRL. Right: Representative
histograms of fluorescence intensity of DNA content of anterior pituitary cells incubated in the presence or absence of 16 kDa PRL.
doi:10.1371/journal.pone.0021806.g003
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lular production of 16 kDa PRL and suggesting that the anterior
pituitary could be a source for circulating 16 kDa PRL.
In our study we demonstrate that the production of N-terminal
PRL fragments in the anterior pituitary gland varies during
the estrous cycle, being higher at proestrus than at diestrus. In
addition, we show that E2 increases anterior pituitary cell content
and release of 16 kDa PRL, suggesting that estrogens are involved
in the increase of N-terminal PRL fragments production observed
during proestrus. In fact, anterior pituitary cells from OVX-E2
treated rats show a higher content of 16 kDa PRL than cells
obtained from male rats [14]. The preovulatory peak of 23 kDa
PRL plasma levels observed in the afternoon of proestrus is due to
the high circulating levels of E2, which increase anterior pituitary
PRL gene expression and PRL release [8]. This hormonal status
may also induce a rise in 16 kDa PRL secretion at this stage of the
estrous cycle. An increase in a given enzymatic product could be
due to an increment in substrate availability and/or an increase in
enzymatic activity. In this regard, it was shown that cathepsin D
activity in corpora lutea varies along the estrous cycle [23] and
that estradiol increases the activity and synthesis of cathepsin D in
uterus [28] and in ovarian and breast cancer cells [29]. Hence,
both an increase in 23 kDa prolactin and anterior pituitary
cathepsin D activity in response to E2 at proestrus could be
responsible for the higher levels of 16 kDa PRL found in the
anterior pituitary at this stage of the estrous cycle.
Our data show that 16 kDa PRL has a proapoptotic action in
anterior pituitary cells and lactotropes. Anterior pituitary cell
homeostasis is regulated by circulating levels of gonadals steroids,
since a peak of apoptosis occurs during proestrus when estradiol
levels are the highest, whereas the maximum proliferation rate
takes place at estrus [1,2]. Estadiol is known to play a key role in
this process, and is required to trigger TNF-a, FasL, dopamine
and bacterial lipopolysaccharide proapoptotic actions in anterior
pituitary cells [3–6,18]. In fact, we observed that the apoptotic
effect of 16 kDa PRL is also an estrogen-dependent process. Dif-
ferent mechanisms have been proposed by which estradiol sensi-
tizes anterior pituitary cells to different apoptotic signals, including
the expression of proapoptic Bax vs antiapoptotic Bcl-2 proteins
[19] and TNF-a/TNFR1 and FasL/Fas systems [3,4]. The
increase in anterior pituitary N-terminal PRL fragments produc-
tion observed at proestrus suggest that, among other factors,
16 kDa PRL is involved in apoptosis of lactotropes occuring at this
stage of the estrous cycle.
In addition, we observed that 16 kDa PRL exerts an anti-
proliferative action in total anterior pituitary cells and lactotropes,
Figure 4. 16 kDa PRL inhibits anterior pituitary cell proliferation. A and B: Anterior pituitary cells from OVX rats were incubated for 24 h with
VEH and FSK, and with or without 16 kDa PRL (10 nM) for the last 4 h. D and E: Anterior pituitary cells from OVX rats were incubated for 24 h with E2,
then for 1 h with E2 and FSK, and for the last 4 h in the same media with or without 16 kDa PRL (10 nM). Proliferation was determined by BrdU
incorporation (3 h) and fluorescence microscopy. A and D: Each column represents the percentage 6 CI (95%) of BrdU-positive cells (n$1000 cells/
group, left) or BrdU-positive lactotropes (n$300 cells/group, right), representative of four independent experiments. Data were analyzed by x
2.
**p,0.01 vs. respective control without 16 kDa PRL. B and E: Representative images of anterior pituitary cells showing immunoreactivity for prolactin
(red) counterstained with DAPI (blue) and BrdU (green). Arrowheads indicate proliferating lactotropes. Scale bar: 50 mm. C and F: Anterior pituitary
cells in culture were incubated with VEH (C) or E2 (F) for 24 h, and with or without 16 kDa PRL (10 nM) for the last 4 h. Cell cycle was analyzed by flow
cytometry using PI. Left: Each column represents the mean 6 SE of the percentage of S-phase cells (n$4 wells/group), representative of three
independent experiments. Data were analyzed by Student’s t test. *p,0.05 vs. respective control without 16 kDa PRL. Right: Representative
histograms of DNA content of anterior pituitary cells incubated in the presence or absence of 16 kDa PRL.
doi:10.1371/journal.pone.0021806.g004
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16 kDa PRL decreases the percentage of endothelial cells in S-
phase, with a cell cycle arrest at G2/M transition and no
concomitant increment of hypodiploid cells [11]. In our studies,
16 kDa PRL induced a decrease in the percentage of cells in S-
phase independently of the presence of E2, whereas only in E2-
treated cells 16 kDa PRL increased the percentage of hypodiploid
cells. This finding leads us to speculate that during proestrus, the
higher levels of 16 kDa PRL isoform induce a decrease in anterior
pituitary cell proliferation, and due to the permissive action of
estrogens present in that moment of the estrous cycle, the arrested
cells die by apoptosis.
Besides its role in anterior pituitary physiology, some aspects of
the biology of 16 kDa PRL can be related to the anterior pituitary
under pathological conditions. Prolactinomas are the most
common pituitary tumors which are usually non metastatic and
non invasive. It is known that prolactinomas are less vascularized
than normal pituitaries [30] and, due to their antiangiogenic
activity, vasoinhibins were suggested to be, at least in part,
responsible for this phenotype [31]. In addition, the antiprolifer-
ative and proapoptotic actions of 16 kDa PRL on anterior
pituitary cells reported here, may contribute to the behavior of
prolactin producing tumors.
In summary, our study indicates that the production of 16 kDa
PRL by the anterior pituitary is variable along the estous cycle and
increased by estrogens. In addition, we demonstrate the
antiproliferative and estradiol-dependent proapoptotic effects of
this vasoinhibin on anterior pituitary cells. These findings suggest
that the action of estrogens on anterior pituitary cell homeostasis
involves the modulation of vasoinhibins production and activity.
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